Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 7, 2023

BP Elements

  • BioPharm International's BP Elements, July 2023
  • Volume 2
  • Issue 7

Eurofins Genomics Blue Heron Launches In-Vitro Transcription mRNA Synthesis Service

Author(s)Grant Playter

Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.

Eurofins Genomics Blue Heron, a biotechnology company specializing in advanced gene synthesis, announced the launch of its in-vitro transcription (IVT) messenger RNA (mRNA) synthesis service on June 29, 2023. According to a company press release, the new synthesis service is designed to offer a comprehensive solution for researchers seeking high-quality, customizable mRNA synthesis with fast turnaround times.

According to the release, the new synthesis service is equipped to handle various applications and includes customizable mRNA synthesis capabilities to meet specific research needs. It is designed for use in molecular biology, drug discovery, vaccine development, and gene therapy, among other fields.

Source: Eurofins Genomics


Related to this article

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.